Member

Bexson Biomedical


Bexson Biomedical develops precision-driven therapies for central nervous system (CNS) disorders, focusing on pain and mental health. The company is advancing a pipeline of subcutaneous drug formulations, led by an IND-ready ketamine compound for moderate/severe acute pain. Bexson also develops wearable, programmable delivery devices to enable controlled, scalable drug administration both in clinical and field settings. Their technology targets unmet needs in pain management, neuropsychiatric conditions, and military medicine.

Industries

N/A

Bexson Biomedical


Patents

Compositions of complexing agents

2026-05-26 • US-12636265-B2

View Details

Complexing agent salt formulations of pharmaceutical compounds

2025-11-18 • US-12472201-B2

View Details

Complexing agent salt formulations of pharmaceutical compounds

2022-12-27 • US-11534454-B2

View Details

Ketamine formulation for subcutaneous injection

2021-04-13 • US-10973780-B2

View Details

Products

A pre-filled, pre-sterilized, Bluetooth-enabled device for programmable, controlled release of subcutaneous therapeutics, including ketamine and other compounds.

A proprietary ketamine salt compound optimized for subcutaneous delivery, achieving high bioavailability and improved tolerance.

Ruggedized wearable drug delivery device optimized for field use, providing rapid, programmable subcutaneous administration for pain, overdose prevention, and battlefield bleeding.

Expertise Areas

  • CNS therapy development
  • Wearable drug delivery technology
  • Clinical-stage drug formulation
  • Military medical device adaptation
  • Show More (2)

Key Technologies

  • Subcutaneous drug delivery systems
  • Programmable electromechanical pumps
  • Bluetooth-enabled medical devices
  • High-concentration, isotonic drug formulations
  • Show More (2)

Key People

Chief Executive Officer

Co-Founder, Chief Scientific Officer

EVP Drug Delivery

EVP Process Development & Manufacturing

SVP Quality & Regulatory

Head of Medicinal Chemistry

View All People

News & Updates

Received for collaborative development of a wearable on-body delivery system.

Discussion of the approach to building wearable, programmable drug delivery devices for pain management.

Forbes article analyzing the potential impact of wearable ketamine delivery systems in pain therapy.

Device evaluated by all five U.S. military branches in August 2023.

Field-optimized device presented to U.S. military innovation leaders.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.